DNMT3A and myelodysplastic syndrome: Mutations in DNMT3A, that catalyzes 5‐methylcytosine methylation occur in a range of hematological malignancies, such as AML and MDS.34 DNA methyltransferase inhibitors, such as azacytidine and decitabine, were the first FDA‐approved epidrugs and are used in first‐line treatment of MDS.